Trial Profile
Safety and effectiveness of CIMAbior in patients with CD20-positive B-cell Non-Hodgkin Lymphoma. Phase IV
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CIMAbiorLNH-IV
- 02 Jan 2018 New trial record